Promensil Post Menopause
Natural health product licensed in Canada
- Licence holder
- PAC Health (Canada) Inc.
- NPN or DIN-HM
- 80070831
- Status
- Active licence
- Licence date
- 5 July 2016
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Esters de lutéine Source : Tagetes erecta - Oléorésine (herbe en fleurs) | 14.4 milligramme | Not calculated |
| Extrait d'isoflavones de trèfle rouge Source : Trifolium pratense- Feuille | 40 mg ÉAI | Not calculated |
| (3R,3'R)-bêta,bêta-Carotène-3,3'-diol Source : Tagetes erecta - Oléorésine (herbe en fleurs) | 0.72 milligramme | Not calculated |
| Vitamine D3 Source : Cholécalciférol Potency : 400 UI | 10 microgrammes | Not calculated |
| Huile de poisson Source : Clupeidae - en entier Potency : 62.6 milligramme Eicosapentaenoic acid | 250 milligramme | Not calculated |
| Huile de poisson Source : Engraulidae - en entier Potency : 62.6 milligramme Eicosapentaenoic acid | 250 milligramme | Not calculated |
| Huile de poisson Source : Clupeidae - en entier Potency : 101.6 milligramme Docosahexaenoic acid | Not specified | Not calculated |
| Huile de poisson Source : Engraulidae - en entier Potency : 101.6 milligramme Docosahexaenoic acid | Not specified | Not calculated |
Non-medicinal ingredients
Lécithine, Dioxyde de titane, Mélange de concentré de tocophérols, Gélatine, Huile de carthame, Dioxyde de silicium, Eau
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Femmes ménopausées et en postménopause | Not specified | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Helps to attenuate/reduce bone mineral density (BMD) loss in post-menopausal women when used in conjunction with adequate amounts of calcium and vitamin D. May reduce severe and frequent menopausal symptoms (such as hot flashes/flushes and/or night sweats). Source of omega-3 fatty acids for the maintenance of good health. Source of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health. Helps support cognitive health and/or brain function. Antioxidant for the maintenance of good health. Antioxidant for the maintenance of eye health. Helps to maintain eyesight in conditions (associated with sunlight damage), such as cataracts and age-related macular degeneration. Helps to support eye health in conditions (associated with sunlight damage), such as cataracts and age-related macular degeneration. Helps to reduce the risk of developing cataracts. Helps to improve macular pigment optical density. A factor in the maintenance of good health. Helps in the development and maintenance of bones. Helps in the development and maintenance of teeth. Helps in the absorption and use of calcium. Helps in the absorption and use of phosphorus. Calcium intake, when combined with sufficient Vitamin D, a healthy diet and regular exercise may reduce the risk of developing osteoporosis. May/helps support cardiovascular health.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
If you currently have or previously had breast cancer or if you have a predisposition to breast cancer, as indicated by an abnormal mammogram and/or biopsy, or if you have a family member with breast cancer, do not use this product.
- Effets indésirables connus
Do not use if you are allergic to plants of the Asteraceae/Compositae/Daisy family.
- Précautions et mises en garde
If you are taking thyroid hormone replacement therapy, consult a health care practitioner prior to use. If you have a liver disorder or develop liver-related symptoms (e.g. abdominal pain, jaundice, dark urine), consult a health care practitioner prior to use. If you have a history of hormonal or gynecological disease including ovarian cancer, endometriosis and/or uterine fibroids, consult a health care practitioner prior to use. Ensure that you are up-to-date on appointed clinical tests such as mammograms and endometrial ultrasounds or biopsies before using this product. If you experience breast pain, discomfort, soreness and/or tenderness, abnormal uterine bleeding including spotting and/or recurrence of menstruation in postmenopausal women, discontinue use and consult a health care practitioner. If you are taking hormone replacement therapy, consult a health care practitioner prior to use. If symptoms worsen, consult a health care practitioner. Do not use if you are pregnant or breastfeeding.
Source
Official Health Canada record, licence 80070831
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.